Nuvilex Inc. (NASDAQ:PMCB) Sees Significant Growth in Short Interest

Nuvilex Inc. (NASDAQ:PMCB) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 177,318 shares, a growth of 181.9% from the December 31st total of 62,893 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average daily volume of 459,349 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 459,349 shares, the days-to-cover ratio is currently 0.4 days. Currently, 2.0% of the shares of the stock are short sold.

Nuvilex Trading Down 3.4%

Shares of PMCB traded down $0.03 during midday trading on Friday, reaching $0.82. The stock had a trading volume of 212,435 shares, compared to its average volume of 390,736. The firm has a 50 day simple moving average of $0.87 and a 200-day simple moving average of $0.92. The firm has a market cap of $8.30 million, a PE ratio of -0.59 and a beta of 0.04. Nuvilex has a one year low of $0.63 and a one year high of $1.90.

Nuvilex (NASDAQ:PMCB) last released its earnings results on Thursday, December 18th. The company reported ($0.32) earnings per share (EPS) for the quarter.

Insider Activity

In other news, CEO Joshua Silverman purchased 40,000 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was bought at an average cost of $0.83 per share, for a total transaction of $33,200.00. Following the completion of the purchase, the chief executive officer directly owned 416,250 shares of the company’s stock, valued at $345,487.50. The trade was a 10.63% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders acquired a total of 110,000 shares of company stock worth $89,000 in the last 90 days. 10.33% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.